Aleksandra Magdalena Skrzyniarz

Aleksandra Magdalena Skrzyniarz

Auto-generated profile, based on publicly available information

Aleksandra Magdalena Skrzyniarz

Medical University of Lublin, Lublin, Poland

Research Focus & Metrics

Academic Career Length

1Year (2026-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 July 2026 in International Journal of Innovative Technologies in Social Science
Verified
Journal Article
Open access
PDF file
JOJulia OzięBło
Julia OzięBło
MKMagdalena Kijowska
Magdalena Kijowska
KKKarolina Klusek
Karolina Klusek
MBMichał Batory
Michał Batory
JJJakub Jakubowski
Jakub Jakubowski
MKMaria Kiełbus
Maria Kiełbus
Premenstrual dysphoric disorder (PMDD) is a cyclic mood disorder affecting a subset of women in the late luteal phase, marked by severe affective and physical symptoms that resolve with menses. It is distinguished from milder premenstrual syndrome (PMS) by symptom severity and functional impairment. PMDD causes substantial distress: women with PMDD have functional impairments comparable to other depressive disorders and increased work absences, and PMDD is associated with higher rates of suicidal ideation and attempts. First-line pharmacotherapy consists of selective serotonin reuptake inhibitors (SSRIs) and hormone-based treatments. SSRIs (e.g. sertraline, fluoxetine, paroxetine, escitalopram) are effective when dosed continuously or in the luteal phase, often producing rapid symptom relief at low doses. Hormonal therapies (e.g. combined oral contraceptives with drospirenone/ethinyl estradiol, GnRH agonists with add-back) can mitigate symptoms by suppressing cyclic ovarian hormone fluctuations. Emerging treatments target PMDD’s neuroendocrine underpinnings: for example, sepranolone (an allopregnanolone antagonist) has shown promising early results. Novel approaches under investigation include neurosteroid modulators, anti-inflammatory strategies, and personalized interventions (genetic or biomarker-driven therapy). This review summarizes current evidence-based pharmacotherapies for PMDD and discusses emerging treatment avenues based on advances in PMDD neurobiology and psychoneuroendocrinology.

21 August 2026 in International Journal of Innovative Technologies in Social Science
Verified
Journal Article
Open access
PDF file
AZAleksandra Zynkowska
Aleksandra Zynkowska
ASAleksandra Magdalena Skrzyniarz
Aleksandra Magdalena Skrzyniarz
MKMaria Kiełbus
Maria Kiełbus
JOJulia OzięBło
Julia OzięBło
MKMagdalena Kijowska
Magdalena Kijowska
NKNadzieja Krasucka
Nadzieja Krasucka
Cholesteatoma is a chronic, locally destructive disease of the middle ear characterized by the presence of keratinizing stratified squamous epithelium within the tympanic cavity and mastoid process. Despite its histologically benign nature, it may lead to the destruction of bony structures, damage to the auditory ossicles, and the development of serious intra- and extracranial complications. Its complex pathogenesis and tendency to recur make cholesteatoma a significant diagnostic and therapeutic challenge. In recent years, substantial progress has been made in both the diagnosis and surgical treatment of cholesteatoma. High-resolution computed tomography and magnetic resonance imaging with non-echo-planar diffusion-weighted imaging (non-EPI DWI) sequences enable accurate assessment of primary, residual, and recurrent lesions. Surgical treatment remains the cornerstone of therapy, while advances in endoscopic techniques have improved visualization of anatomical structures and enhanced surgical effectiveness while reducing invasiveness. Artificial intelligence systems are also gaining increasing importance in supporting imaging analysis, treatment planning, and clinical decision-making. The aim of this review is to present current advances in the diagnosis and surgical management of cholesteatoma, with particular emphasis on modern imaging techniques, endoscopic ear surgery, and applications of artificial intelligence. The development of these technologies may contribute in the future to improved treatment outcomes and reduced risk of disease recurrence.

2 July 2026 in International Journal of Innovative Technologies in Social Science
Verified
Journal Article
Open access
PDF file
JJJakub Jakubowski
Jakub Jakubowski
KKKarol Kraska
Karol Kraska
NKNadzieja Krasucka
Nadzieja Krasucka
AZAleksandra Zynkowska
Aleksandra Zynkowska
ASAleksandra Skrzyniarz
Aleksandra Skrzyniarz
MBMichał Batory
Michał Batory
Anderson-Fabry disease (FD) is a rare, X-linked lysosomal storage disorder in which the progressive accumulation of globotriaosylceramide (Gb3) leads to widespread multi-organ damage, with cardiac involvement serving as the primary cause of mortality. This comprehensive review aims to summarize the current state of knowledge regarding the clinical application of electrocardiography (ECG) as a pivotal and cost-effective tool in the management of patients with FD. The paper systematically categorizes ECG findings across the various stages of the disease's progression. Early stages are typically characterized by a shortened PR interval and increased QRS complex voltages, which frequently manifest prior to the development of structural changes identifiable through echocardiography. In the more advanced stages of the disease, the predominant features include signs of left ventricular hypertrophy (LVH), ST-segment depressions, and deep T-wave inversions, which often mimic the presentation of hypertrophic cardiomyopathy or myocardial ischemia. Furthermore, this review discusses the evolution of conduction disturbances, including atrioventricular blocks and atrial fibrillation, while emphasizing the absolute necessity of Holter monitoring for effective arrhythmia risk stratification. The impact of enzyme replacement therapy (ERT) on the stabilization of ECG patterns is evaluated, indicating that early clinical intervention is crucial for the prevention of irreversible electrical remodeling. In conclusion, despite the ongoing development of advanced imaging modalities, the standard 12-lead ECG remains a fundamental and indispensable tool that shortens the diagnostic odyssey and allows for the precise monitoring of treatment efficacy in Fabry disease.

2 July 2026 in International Journal of Innovative Technologies in Social Science
Verified
Journal Article
Open access
NKNadzieja Krasucka
Nadzieja Krasucka
JJJakub Jakubowski
Jakub Jakubowski
MBMichał Batory
Michał Batory
KKKarolina Klusek
Karolina Klusek
MKMagdalena Kijowska
Magdalena Kijowska
KKKarol Kraska
Karol Kraska
Chronic non-healing wounds constitute a significant health concern and impose a substantial financial burden on healthcare systems. This creates a pressing need for advanced solutions capable of improving therapeutic efficacy. The aim of this review article is to analyze the current state of knowledge regarding the application of smart dressings and 3D and 4D bioprinting technologies in the treatment of chronic wounds. The methodology was based on a critical review and synthesis of scientific literature in the fields of biomaterials engineering and regenerative medicine. Contemporary hydrogel-based matrices integrated with biosensors and machine learning algorithms effectively transform passive mechanical wound protection into an automated system for monitoring the wound microenvironment and actively responding to its changes. Concurrently, 3D bioprinting techniques enable precise architectural reconstruction of tissues and the fabrication of grafts tailored to the unique size, shape, and depth of individual injuries. Although smart dressing technologies, 3D and 4D bioprinting are undergoing intensive development, additional preclinical and clinical studies are required to establish their safety and efficacy profiles, which is a prerequisite for the development of national regulatory standards.

18 September 2026 in International Journal of Innovative Technologies in Social Science
Verified
Journal Article
Open access
PDF file
MKMagdalena Kijowska
Magdalena Kijowska
KKKarolina Klusek
Karolina Klusek
MBMichał Batory
Michał Batory
JJJakub Jakubowski
Jakub Jakubowski
KKKarol Kraska
Karol Kraska
JOJulia OzięBło
Julia OzięBło
Opioid-free anesthesia (OFA) and opioid-sparing anesthesia (OSA) have emerged from two converging developments in perioperative medicine: first, the need to reduce opioid-related adverse drug events such as postoperative nausea and vomiting (PONV), respiratory depression, ileus, sedation, and possibly persistent postoperative use; and second, the maturation of enhanced recovery pathways built around multimodal, function-oriented analgesia. In contemporary evidence, however, strict elimination of intraoperative opioids has not shown universal superiority over well-conducted opioid-based anesthesia (OBA) for postoperative pain control or 24-hour opioid consumption. The most reproducible benefit of OFA is lower PONV in selected settings, whereas the most important safety signal is regimen-dependent bradycardia and hemodynamic instability, especially in dexmedetomidine-heavy protocols. By contrast, broader OSA strategies, particularly when built on acetaminophen, NSAIDs, regional anesthesia, judicious total intravenous anesthesia (TIVA), and selected adjuvants such as ketamine or lidocaine, are aligned with ERAS and other major perioperative guidance and have the strongest overall clinical support. This narrative review examines definitions, mechanisms, pharmacology, protocols, clinical outcomes, limitations, and practical applications of OFA and OSA in modern perioperative care. Conclusion: contemporary perioperative practice is better supported by individualized opioid stewardship and multimodal opioid-sparing care than by a dogmatic “zero-opioid” rule. OFA remains a reasonable option in selected phenotypes and procedures, but current evidence does not justify its routine use as a default replacement for all opioid-inclusive techniques.

20 August 2026 in International Journal of Innovative Technologies in Social Science
Verified
Journal Article
Open access
PDF file
ASAleksandra Magdalena Skrzyniarz
Aleksandra Magdalena Skrzyniarz
MKMaria Kiełbus
Maria Kiełbus
JOJulia OzięBło
Julia OzięBło
MKMagdalena Kijowska
Magdalena Kijowska
KKKarolina Klusek
Karolina Klusek
AZAleksandra Zynkowska
Aleksandra Zynkowska
Acne vulgaris is one of the most common chronic inflammatory skin diseases with a complex and multifactorial pathogenesis, including keratinization disorders, excessive sebum production, skin microbiome dysbiosis, inflammatory processes, and hormonal and genetic factors. Despite the availability of numerous effective therapies, such as retinoids, antibiotics, and hormonal therapy, their use is still associated with limitations, including adverse effects, unsatisfactory results, the risk of antibiotic resistance, and disease recurrence. Consequently, contemporary dermatology is increasingly focusing on the development of personalized therapies and modern technologies supporting the diagnosis and treatment of acne. The aim of this study was to review current trends in the diagnosis and treatment of acne vulgaris, which are aimed at combining digital and biotechnological tools and exploring new treatment alternatives to improve treatment effectiveness. Data were analyzed regarding the use of artificial intelligence algorithms in assessing skin lesions, the use of nanocarriers in drug delivery, and the importance of genetic, immunological, hormonal, and microbiological factors in the pathogenesis of acne. The complex and multifactorial nature of acne vulgaris pathogenesis suggests that effective future therapies will require a multifaceted approach that takes into account individual patient predispositions.